# Challenges and Advances in the Detection of Leukemic Blasts in Cerebrospinal Fluid in Pediatric Acute Lymphoblastic Leukemia

## TL;DR

This paper reviews methods for detecting leukemia cells in brain fluid in children with leukemia, emphasizing the importance of accurate detection to guide treatment and prevent relapse.

## Contribution

The paper provides a comprehensive review of current diagnostic techniques and highlights the need for standardized protocols in detecting leukemic blasts in cerebrospinal fluid.

## Key findings

- Cytomorphology is limited in sensitivity for detecting rare leukemia cells in cerebrospinal fluid.
- Flow cytometry offers higher sensitivity and is increasingly used to confirm ambiguous cases.
- Detecting even small numbers of leukemia cells in CSF is linked to higher relapse risk and worse outcomes.

## Abstract

Checking whether leukemia has spread to the brain is a key part of caring for children with acute lymphoblastic leukemia. When leukemia cells are found in the fluid surrounding the brain and spinal cord, the disease is harder to treat and the risk of relapse is higher, requiring more intensive therapy. Even very small numbers of leukemia cells in this fluid can increase the risk of leukemia coming back. Advances in treatments designed to protect the brain and spinal cord have greatly improved survival for children with acute lymphoblastic leukemia. However, detecting rare leukemia cells remains challenging because only small amounts of fluid and low numbers of cells are available for testing. This review describes current available methods used to identify leukemia cells in brain and spinal cord fluid, highlighting their importance, strengths, and limitations in guiding treatment and preventing relapses.

Central nervous system (CNS) evaluation for leukemic involvement is essential both at initial diagnosis and throughout relapse surveillance in childhood acute lymphoblastic leukemia (ALL). Accurate CNS risk classification is a cornerstone of individualized chemotherapy and has significantly advanced treatment strategies. However, detecting leukemic cells in the cerebrospinal fluid (CSF) is challenging, particularly when only a small number of cells are present. While cytomorphology remains a standard diagnostic method, it is limited by low sensitivity and interobserver variability, especially in low-cellularity or equivocal samples. Flow cytometry offers superior sensitivity and specificity and is increasingly recommended to confirm or clarify ambiguous findings. Current guidelines support the use of both cytomorphologic review and flow cytometry to maximize diagnostic accuracy. Evidence consistently demonstrates that any detectable CSF blasts—even in the setting of low WBC counts—are associated with increased risk of CNS relapse and poorer outcomes, underscoring the importance of risk-adapted CNS-directed therapy. Although the prognostic significance of isolated flow-only positivity remains under study, emerging data suggest that timely therapeutic intensification may mitigate adverse outcomes. Additional modalities, including advanced flow cytometry and molecular assays, may further refine CSF assessment in the future. This review summarizes current diagnostic approaches and highlights the need for standardized protocols for CSF evaluation in pediatric ALL.